<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755820</url>
  </required_header>
  <id_info>
    <org_study_id>5457</org_study_id>
    <nct_id>NCT00755820</nct_id>
  </id_info>
  <brief_title>Food Exposure Therapy in Anorexia Nervosa</brief_title>
  <official_title>Food Exposure Therapy in Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hilda &amp; Preston Davis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to determine whether a medication called D-cycloserine (DCS) in&#xD;
      combination with a type of psychotherapy called Exposure Therapy is helpful to patients with&#xD;
      anorexia nervosa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a research study to determine whether a medication called D-cycloserine (DCS) in&#xD;
      combination with a type of psychotherapy called Exposure Therapy is helpful to patients with&#xD;
      anorexia nervosa. DCS is approved by the FDA as an antibiotic medication, but has not been&#xD;
      approved by the FDA for the treatment of anorexia nervosa. Past studies have found that DCS&#xD;
      together with Exposure Therapy can help people with height phobia, social phobia, and&#xD;
      obsessive compulsive disorder. Anorexia nervosa often includes phobia-like fears, obsessive&#xD;
      thoughts, and compulsive rituals, so the current study aims to determine whether DCS paired&#xD;
      with Exposure Therapy can also help people with anorexia nervosa. Anorexia nervosa is a&#xD;
      disorder characterized by self-starvation, extreme weight loss, and difficulty maintaining a&#xD;
      normal weight. You have been asked to participate in this study because you have been given a&#xD;
      diagnosis of anorexia nervosa. In this study you will receive one of three therapies:&#xD;
      Exposure Therapy with DCS, Exposure Therapy with placebo (inactive medication), or Treatment&#xD;
      as Usual. You will participate in a total of four test meals in a laboratory setting. A total&#xD;
      of 70 individuals with anorexia nervosa will participate in this study. Twenty individuals&#xD;
      who have never had an eating disorder will participate in one portion of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>EXP-DCS/Exposure-D-cycloserine</arm_group_label>
    <description>Exposure Therapy + D-Cycloserine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXP-PBO</arm_group_label>
    <description>Exposure Therapy + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP</arm_group_label>
    <description>Supportive psychotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exposure Therapy + D-Cycloserine</intervention_name>
    <description>Exposure therapy with d-cycloserine medication</description>
    <arm_group_label>EXP-DCS/Exposure-D-cycloserine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exposure Therapy + Placebo</intervention_name>
    <description>Exposure therapy with placebo medication</description>
    <arm_group_label>EXP-PBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Supportive Psychotherapy</intervention_name>
    <description>Supportive psychotherapy</description>
    <arm_group_label>SP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients receiving treatment for anorexia nervosa&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Patients:&#xD;
&#xD;
          -  DSM-IV-TR™ diagnosis of anorexia nervosa (restricting or binge-purge subtype) on&#xD;
             admission&#xD;
&#xD;
          -  Subjects will have achieved 90% of ideal body weight (IBW)&#xD;
&#xD;
          -  Age 18-45&#xD;
&#xD;
          -  Medically stable&#xD;
&#xD;
          -  Participation in inpatient treatment&#xD;
&#xD;
          -  Subjects must have signed informed consent document indicating that they understand&#xD;
             the purpose of and procedures required for the study and are willing to participate in&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria for Patients:&#xD;
&#xD;
          -  Any other current major Axis I disorder, except OCD or MDD (mild)&#xD;
&#xD;
          -  On psychotropic medication, including benzodiazepines (At the start of the study,&#xD;
             subjects will be free of fluoxetine for 4 weeks, and free of all other medications for&#xD;
             a minimum of 2 weeks.)&#xD;
&#xD;
          -  History of a seizure disorder&#xD;
&#xD;
          -  Abnormal liver function&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Known hypersensitivity to D-cycloserine&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Acute suicidality (suicidality or self injury in the last 3 months)&#xD;
&#xD;
        Inclusion Criteria for Healthy Controls:&#xD;
&#xD;
          -  BMI ≥ 19.0 kg/m2&#xD;
&#xD;
          -  Age 18-45 years&#xD;
&#xD;
          -  Subjects must have signed informed consent document indicating that they understand&#xD;
             the purpose of and procedures required for the study and are willing to participate in&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria for Healthy Controls:&#xD;
&#xD;
          -  Current Major Axis I disorder (including Eating Disorder, Major Depression,Bipolar&#xD;
             Disorder, Schizophrenia, Substance Abuse/Dependence) History of an Eating Disorder&#xD;
&#xD;
          -  Current use of psychotropic medication or other medication known to affect mood and/or&#xD;
             anxiety (e.g. b-agonist inhalers, oral steroids)&#xD;
&#xD;
          -  Major medical condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Steinglass, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CUMC/NYSPI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2008</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

